

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Andrew Simon Bell, et al : :

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: PDE9 Inhibitors For Treating Type 2 Diabetes, :  
Metabolic Syndrome, and Cardiovascular  
Diseases

Mail Stop Patent Applications  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.


Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: Apr 20/04

Respectfully submitted,  
  
William F. Muholland, II  
Attorney for Applicant(s)  
Reg. No. 45,684

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-5590

EXPRESS MAIL NO. EU 271824933US

INFORMATION DISCLOSURE CITATION Page 1 of 3 (Use several sheets if necessary)								ATTY. DOCKET NO. PC25666A			SERIAL NO. To Be Assigned		
								APPLICANT Andrew Simon Bell, et al.			GROUP To Be Assigned		
								FILING DATE Herewith					

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	6	0	3	7	3	4	6	14 March 00	Doherty, Jr et al	514	258	
	US	2	5	0	3	0	5	9	4 April 50	Miescher et al			
	US	4	7	0	3	0	6	3	27 Oct 87	Imai et al	514	603	
	US	3	3	8	1	0	0	9	30 April 68	Palazzo, et al.	260	268	
	US	4	2	5	2	7	2	1	24 Feb 81	Silvestrini et al	260	243.3	
	US	4	1	8	8	3	9	0	12 Feb 80	Campbell	424	251	
	US	4	0	2	6	8	9	4	31 May 77	Winn et al.	260	256.4	
	US	3	5	1	1	8	3	6	12 May 70	Hess	260	256.4	
	US	4	3	1	5	0	0	7	9 Feb 82	Manoury	424	251	
	US	3	5	2	7	7	6	1	8 Sept 70	Archibald, et al.	260	293	
	US	6	5	6	6	3	6	0	20 May 03	Niewohner et al.	514	243	
	US	2003	1	4	9	0	3	3	7 Aug 03	Niewohner et al.	514	28.5	
	US	2003	01	9	5	2	0	5	16 Oct 03	DeNinno, et al.	514	228.5	
	US	2004	00	2	3	9	8	9	5 Feb 04	Fryburg et al.	514	262.1	
	US	3	9	9	7	6	6	6	14 Dec 76	Witte et al	424	250	

### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
	WO	0	0	1	2	0	7	5	9 March 00	International	A61K	31/13	YES	NO
	WO	2004	0	1	8	4	7	4	4 March 04	International	C07D	487/04		XX
	DE	1	0	2	3	8	7	24		DE	C07D	487/04		XX

### ARTICLES

		D. A. Fisher et al., J. Biol. Chemistry, vol. 273, no. 25, pgs 15559-15564, 1998
		G. J. Etgen, et al., Diabetes, 46, 1997, pgs 1915-1919
		Berge, et al., J. Pharm. Sci, 66, 1977, pgs 1-19
		W. J. Thompson, et al., Biochem., 1979, 18, pg 5228

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

EXPRESS MAIL NO. EV271824533US